Gambling, Resorts & Casinos
Compare Stocks
5 / 10Stock Comparison
BRSL vs GENI vs DKNG vs PENN vs SRAD
Revenue, margins, valuation, and 5-year total return — side by side.
Internet Content & Information
Gambling, Resorts & Casinos
Gambling, Resorts & Casinos
Software - Application
BRSL vs GENI vs DKNG vs PENN vs SRAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Gambling, Resorts & Casinos | Internet Content & Information | Gambling, Resorts & Casinos | Gambling, Resorts & Casinos | Software - Application |
| Market Cap | $2.35B | $1.17B | $12.50B | $2.24B | $4.04B |
| Revenue (TTM) | $2.51B | $669M | $6.05B | $6.96B | $1.33B |
| Net Income (TTM) | $147M | $-112M | $4M | $-843M | $70M |
| Gross Margin | 47.1% | 22.9% | 41.3% | 30.6% | 38.2% |
| Operating Margin | 29.8% | -18.1% | -0.2% | -7.9% | 9.3% |
| Forward P/E | 14.7x | 52.4x | 99.1x | 23.0x | 33.1x |
| Total Debt | $4.25B | $30M | $1.93B | $8.38B | $63M |
| Cash & Equiv. | $1.45B | $281M | $1.60B | $687M | $365M |
BRSL vs GENI vs DKNG vs PENN vs SRAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Brightstar Lottery (BRSL) | 100 | 48.2 | -51.8% |
| Genius Sports Limit… (GENI) | 100 | 25.5 | -74.5% |
| DraftKings Inc. (DKNG) | 100 | 52.4 | -47.6% |
| PENN Entertainment,… (PENN) | 100 | 23.1 | -76.9% |
| Sportradar Group AG (SRAD) | 100 | 60.3 | -39.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BRSL vs GENI vs DKNG vs PENN vs SRAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BRSL carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 2 yrs, beta 0.91, yield 30.8%
- 31.3% 10Y total return vs DKNG's 157.3%
- Lower P/E (14.7x vs 23.0x)
- 5.9% margin vs GENI's -16.7%
GENI ranks third and is worth considering specifically for growth exposure.
- Rev growth 31.0%, EPS growth -63.0%, 3Y rev CAGR 25.2%
- 31.0% revenue growth vs BRSL's -0.0%
Among these 5 stocks, DKNG doesn't own a clear edge in any measured category.
PENN is the clearest fit if your priority is momentum.
- +6.7% vs GENI's -53.1%
SRAD is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.65, Low D/E 6.4%, current ratio 1.17x
- Beta 0.65, current ratio 1.17x
- Beta 0.65 vs GENI's 1.50
- 2.7% ROA vs GENI's -11.1%, ROIC 12.9% vs -16.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 31.0% revenue growth vs BRSL's -0.0% | |
| Value | Lower P/E (14.7x vs 23.0x) | |
| Quality / Margins | 5.9% margin vs GENI's -16.7% | |
| Stability / Safety | Beta 0.65 vs GENI's 1.50 | |
| Dividends | 30.8% yield; 2-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +6.7% vs GENI's -53.1% | |
| Efficiency (ROA) | 2.7% ROA vs GENI's -11.1%, ROIC 12.9% vs -16.6% |
BRSL vs GENI vs DKNG vs PENN vs SRAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BRSL vs GENI vs DKNG vs PENN vs SRAD — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BRSL leads in 2 of 6 categories
GENI leads 0 • DKNG leads 0 • PENN leads 0 • SRAD leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
BRSL leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PENN is the larger business by revenue, generating $7.0B annually — 10.4x GENI's $669M. BRSL is the more profitable business, keeping 5.9% of every revenue dollar as net income compared to GENI's -16.7%. On growth, DKNG holds the edge at +42.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.5B | $669M | $6.1B | $7.0B | $1.3B |
| EBITDAEarnings before interest/tax | $1.1B | -$50M | $266M | -$105M | $308M |
| Net IncomeAfter-tax profit | $147M | -$112M | $4M | -$843M | $70M |
| Free Cash FlowCash after capex | -$456M | $37M | $612M | -$169M | $363M |
| Gross MarginGross profit ÷ Revenue | +47.1% | +22.9% | +41.3% | +30.6% | +38.2% |
| Operating MarginEBIT ÷ Revenue | +29.8% | -18.1% | -0.2% | -7.9% | +9.3% |
| Net MarginNet income ÷ Revenue | +5.9% | -16.7% | +0.1% | -12.1% | +5.2% |
| FCF MarginFCF ÷ Revenue | -18.2% | +5.5% | +10.1% | -2.4% | +27.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | +37.0% | +42.8% | +8.2% | +13.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -70.1% | +33.8% | +192.9% | +37.5% | -128.5% |
Valuation Metrics
Evenly matched — BRSL and PENN each lead in 2 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, BRSL's 4.7x EV/EBITDA is more attractive than DKNG's 49.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.3B | $1.2B | $12.5B | $2.2B | $4.0B |
| Enterprise ValueMkt cap + debt − cash | $5.2B | $924M | $12.8B | $9.9B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -1269.00x | -10.83x | -3113.58x | -2.88x | 38.69x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.65x | 52.42x | 99.14x | 22.95x | 33.09x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.68x |
| EV / EBITDAEnterprise value multiple | 4.67x | — | 49.42x | 13.81x | 17.74x |
| Price / SalesMarket cap ÷ Revenue | 0.94x | 1.75x | 2.06x | 0.32x | 2.77x |
| Price / BookPrice ÷ Book value/share | 1.57x | 1.68x | 19.81x | 1.33x | 3.79x |
| Price / FCFMarket cap ÷ FCF | — | 18.18x | 19.31x | — | 8.98x |
Profitability & Efficiency
Evenly matched — BRSL and SRAD each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
BRSL delivers a 9.2% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-35 for PENN. GENI carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PENN's 4.58x. On the Piotroski fundamental quality scale (0–9), DKNG scores 7/9 vs GENI's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.2% | -15.5% | +0.5% | -34.7% | +7.3% |
| ROA (TTM)Return on assets | +1.6% | -11.1% | +0.1% | -5.7% | +2.7% |
| ROICReturn on invested capital | +11.7% | -16.6% | -0.9% | +1.8% | +12.9% |
| ROCEReturn on capital employed | +12.9% | -15.3% | -0.6% | +2.0% | +5.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 | 7 | 5 | 4 |
| Debt / EquityFinancial leverage | 2.67x | 0.04x | 3.06x | 4.58x | 0.06x |
| Net DebtTotal debt minus cash | $2.8B | -$250M | $330M | $7.7B | -$302M |
| Cash & Equiv.Liquid assets | $1.4B | $281M | $1.6B | $687M | $365M |
| Total DebtShort + long-term debt | $4.3B | $30M | $1.9B | $8.4B | $63M |
| Interest CoverageEBIT ÷ Interest expense | 3.66x | -136.57x | 1.92x | -1.02x | 2.02x |
Total Returns (Dividends Reinvested)
Evenly matched — GENI and PENN each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BRSL five years ago would be worth $10,703 today (with dividends reinvested), compared to $1,936 for PENN. Over the past 12 months, PENN leads with a +6.7% total return vs GENI's -53.1%. The 3-year compound annual growth rate (CAGR) favors GENI at 5.5% vs PENN's -13.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -15.6% | -55.8% | -29.3% | +12.9% | -41.5% |
| 1-Year ReturnPast 12 months | -2.4% | -53.1% | -27.3% | +6.7% | -41.4% |
| 3-Year ReturnCumulative with dividends | -33.8% | +17.4% | +4.3% | -35.3% | +5.7% |
| 5-Year ReturnCumulative with dividends | +7.0% | -74.6% | -47.9% | -80.6% | -45.5% |
| 10-Year ReturnCumulative with dividends | +31.3% | -52.4% | +157.3% | +11.9% | -45.5% |
| CAGR (3Y)Annualised 3-year return | -12.8% | +5.5% | +1.4% | -13.5% | +1.9% |
Risk & Volatility
Evenly matched — PENN and SRAD each lead in 1 of 2 comparable metrics.
Risk & Volatility
SRAD is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than GENI's 1.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PENN currently trades 81.4% from its 52-week high vs GENI's 34.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.91x | 1.50x | 1.12x | 1.34x | 0.65x |
| 52-Week HighHighest price in past year | $18.57 | $13.73 | $48.78 | $20.61 | $32.22 |
| 52-Week LowLowest price in past year | $12.02 | $3.83 | $20.46 | $11.65 | $11.66 |
| % of 52W HighCurrent price vs 52-week peak | +68.3% | +34.7% | +51.7% | +81.4% | +42.3% |
| RSI (14)Momentum oscillator 0–100 | 47.1 | 45.3 | 55.1 | 55.1 | 38.7 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 5.6M | 12.9M | 4.4M | 3.6M |
Analyst Outlook
BRSL leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: BRSL as "Buy", GENI as "Buy", DKNG as "Buy", PENN as "Buy", SRAD as "Buy". Consensus price targets imply 153.9% upside for GENI (target: $12) vs 18.5% for PENN (target: $20). BRSL is the only dividend payer here at 30.80% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.50 | $12.10 | $36.88 | $19.88 | $21.75 |
| # AnalystsCovering analysts | 6 | 19 | 48 | 47 | 20 |
| Dividend YieldAnnual dividend ÷ price | +30.8% | — | — | — | — |
| Dividend StreakConsecutive years of raises | 2 | 1 | — | — | — |
| Dividend / ShareAnnual DPS | $3.91 | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +11.5% | 0.0% | +6.6% | +15.8% | +2.9% |
BRSL leads in 2 of 6 categories — strongest in Income & Cash Flow and Analyst Outlook. 4 categories are tied.
BRSL vs GENI vs DKNG vs PENN vs SRAD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BRSL or GENI or DKNG or PENN or SRAD a better buy right now?
For growth investors, Genius Sports Limited (GENI) is the stronger pick with 31.
0% revenue growth year-over-year, versus -0. 0% for Brightstar Lottery (BRSL). Sportradar Group AG (SRAD) offers the better valuation at 38. 7x trailing P/E (33. 1x forward), making it the more compelling value choice. Analysts rate Brightstar Lottery (BRSL) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BRSL or GENI or DKNG or PENN or SRAD?
On forward P/E, Brightstar Lottery is actually cheaper at 14.
7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — BRSL or GENI or DKNG or PENN or SRAD?
Over the past 5 years, Brightstar Lottery (BRSL) delivered a total return of +7.
0%, compared to -80. 6% for PENN Entertainment, Inc. (PENN). Over 10 years, the gap is even starker: DKNG returned +157. 3% versus GENI's -52. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BRSL or GENI or DKNG or PENN or SRAD?
By beta (market sensitivity over 5 years), Sportradar Group AG (SRAD) is the lower-risk stock at 0.
65β versus Genius Sports Limited's 1. 50β — meaning GENI is approximately 130% more volatile than SRAD relative to the S&P 500. On balance sheet safety, Genius Sports Limited (GENI) carries a lower debt/equity ratio of 4% versus 5% for PENN Entertainment, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BRSL or GENI or DKNG or PENN or SRAD?
By revenue growth (latest reported year), Genius Sports Limited (GENI) is pulling ahead at 31.
0% versus -0. 0% for Brightstar Lottery (BRSL). On earnings-per-share growth, the picture is similar: Sportradar Group AG grew EPS 200. 0% year-over-year, compared to -184. 4% for PENN Entertainment, Inc.. Over a 3-year CAGR, DKNG leads at 39. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BRSL or GENI or DKNG or PENN or SRAD?
Sportradar Group AG (SRAD) is the more profitable company, earning 7.
8% net margin versus -16. 7% for Genius Sports Limited — meaning it keeps 7. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRSL leads at 35. 1% versus -15. 6% for GENI. At the gross margin level — before operating expenses — BRSL leads at 41. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BRSL or GENI or DKNG or PENN or SRAD more undervalued right now?
On forward earnings alone, Brightstar Lottery (BRSL) trades at 14.
7x forward P/E versus 99. 1x for DraftKings Inc. — 84. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GENI: 153. 9% to $12. 10.
08Which pays a better dividend — BRSL or GENI or DKNG or PENN or SRAD?
In this comparison, BRSL (30.
8% yield) pays a dividend. GENI, DKNG, PENN, SRAD do not pay a meaningful dividend and should not be held primarily for income.
09Is BRSL or GENI or DKNG or PENN or SRAD better for a retirement portfolio?
For long-horizon retirement investors, Brightstar Lottery (BRSL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
91), 30. 8% yield). Genius Sports Limited (GENI) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BRSL: +31. 3%, GENI: -52. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BRSL and GENI and DKNG and PENN and SRAD?
These companies operate in different sectors (BRSL (Consumer Cyclical) and GENI (Communication Services) and DKNG (Consumer Cyclical) and PENN (Consumer Cyclical) and SRAD (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: BRSL is a small-cap income-oriented stock; GENI is a small-cap high-growth stock; DKNG is a mid-cap high-growth stock; PENN is a small-cap quality compounder stock; SRAD is a small-cap quality compounder stock. BRSL pays a dividend while GENI, DKNG, PENN, SRAD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
- Sector: Communication Services
- Market Cap > $100B
- Revenue Growth > 18%
- Gross Margin > 13%
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.